Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Current Liabilities (2022 - 2025)

Atara Biotherapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $14.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 88.91% year-over-year to $14.9 million; the TTM value through Dec 2025 reached $14.9 million, down 88.91%, while the annual FY2025 figure was $14.9 million, 88.91% down from the prior year.
  • Total Current Liabilities reached $14.9 million in Q4 2025 per ATRA's latest filing, down from $18.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $180.7 million in Q1 2024 to a low of $14.6 million in Q2 2025.
  • Average Total Current Liabilities over 4 years is $87.3 million, with a median of $76.7 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 166.21% in 2024, then crashed 90.18% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $78.9 million in 2022, then soared by 80.22% to $142.2 million in 2023, then fell by 5.38% to $134.6 million in 2024, then tumbled by 88.91% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Total Current Liabilities are $14.9 million (Q4 2025), $18.1 million (Q3 2025), and $14.6 million (Q2 2025).